{
  "docId": "019de073-ace7-72fb-abe1-daa413db1006",
  "docSlug": "7bdf7da39a85a072a380631ad1d0379d",
  "documentTitle": "Cabaletta Bio | Investor Presentation Deck | 23 slides",
  "authorId": "cabaletta-bio",
  "authorName": "Cabaletta Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 23,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "The slide highlights clinical efficacy and safety data from a Nature Medicine study (Mackensen et al., 2022) relevant to the company's CABA-201 construct.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ace7-72fb-abe1-daa413db1006/10",
  "deckHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006",
  "deckJsonHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006.json",
  "deckAnchorHref": "/decks/019de073-ace7-72fb-abe1-daa413db1006#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.18,
        "x": 0.42,
        "y": 0.5
      },
      "kind": "chart",
      "text": "SLE disease activity (SLEDAI-2K) at baseline vs 3 months",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3aad1bd-2fd4-4cfd-9bc7-c2580609a722",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.65,
        "y": 0.18
      },
      "kind": "chart",
      "text": "CAR T cells and CD19+ B cells over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c06b25c-4732-4456-905f-173adca251a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "SLE - Systemic lupus erythematosus; scFv - Single chain variable fragment; SLEDAI-2K - Systemic Lupus Erythematosus Disease Activity Index 2000; CRS - Cytokine release syndrome; ICANS - Immune effector cell-associated neurotoxicity syndrome",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2443a4d8-c60c-420b-a4e6-1ded3dcfad99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "Clinical & serologic responses by 3 mo. after 4-1BB CD19-CAR T therapy with promising safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11ebd4f6-f2f7-4733-b8bd-14cf6704c197",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "5/5 refractory SLE patients treated with 4-1BB CD19-CAR T resulting in rapid, deep and transient depletion of CD19+ B cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "187fb77a-ce9b-4500-8b6e-ee7f9e15374d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.65,
        "y": 0.68
      },
      "kind": "list",
      "text": "Durable clinical responses: 5-17 months of follow up; Responses maintained with no need for SLE-associated medications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "890bdb84-9a56-4941-ada2-e5e749a1139d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.65,
        "y": 0.5
      },
      "kind": "list",
      "text": "Repopulation of healthy B cells: New B cells reappeared in 5/5 patients between 2-5 months; Limited decline in vaccination titers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd4fe152-6368-48ad-a836-eedd47b1b1d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Academic clinical data: Immune system reset in 5/5 SLE patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22ee7f30-a025-4fc5-b899-2b554619f0f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Exclusive translational research partnership with lead investigator informing our CD19 clinical strategy",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "372f1032-6fc9-4e3d-b897-f02721fc4acf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}